John Risinger

John Risinger is a Professor in the Department of Obstetrics, Gynecology and Reproductive Biology at Michigan State University, and Director of the Division of Gynecologic Oncology. His research focuses on molecular mechanisms underlying endometrial and ovarian cancers, particularly obesity-related microRNAs and metastasis prediction tools. He holds a Ph.D. in Molecular Biology and Genetics from the University of North Carolina at Chapel Hill and has prior experience at the National Cancer Institute. His lab develops diagnostic and therapeutic strategies targeting cancer genes and pathways, with emphasis on improving patient outcomes through molecular profiling.

Education: Ph.D. in Molecular Biology and Genetics (UNC Chapel Hill), Postdoctoral training at the National Cancer Institute. Former roles include Director of the Program of Women’s Cancers at the Curtis and Elizabeth Anderson Cancer Institute.

Research Interests: Molecular defects in gynecologic cancers, microRNA regulation, metastasis prediction, and drug resistance mechanisms. The lab investigates novel therapeutic targets (e.g., polyamine pathways, MIG-6 protein) and racial disparities in cancer outcomes through multi-omic analyses.

Recent studies highlight advancements in understanding obesity-linked microRNAs in endometrial cancer, development of metastasis prediction tools, and identification of biomarkers for aggressive tumors. His work bridges clinical and molecular perspectives to address unmet needs in gynecologic oncology.

Scientific Awards: None explicitly listed. Grants and Advising: Not detailed in provided text, but extensive collaboration with institutions like the NRG Oncology Group and Gynecologic Oncology Group. Lab: The Risinger Lab at MSU focuses on translational research in gynecologic cancers.